Online ISSN: 1884-4111 Print ISSN: 0033-8303
Radioisotopes 69(6): 207-212 (2020)

連載講座Serial Lecture

TRT・TATへの期待基礎研究・開発研究の観点からA Perspective in TRT and TATBasic and Translational Sciences

国立研究開発法人量子科学技術研究開発機構放射線医学総合研究所National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Techonology

発行日:2020年6月15日Published: June 15, 2020


Targeted radionuclide therapy (TRT) uses radioisotopes (RIs) that emit cytotoxic particle radiation and has been established as a therapeutic option for cancer. TRT has a long history since 131I was used for the treatment of thyroid diseases. β-particle emitters such as 131I and 90Y have been utilized mainly in TRT. Recently progress on radiochemistry and accelerator engineering make targeted alpha therapy (TAT) an attractive therapeutic option of cancer therapy because α-particle beam has higher cytotoxicity than β-particle. α-particle beam has very short path length; when precisely delivered to target, only target cells should be killed sparing the surrounding non-target cells. Research and development for TAT is now under active investigation.

Key words: radioisotopes; targeted radionuclide therapy (TRT); targeted alpha therapy (TAT); radiopharmacology; radiation oncology

This page was created on 2020-02-25T10:31:55.658+09:00
This page was last modified on 2020-06-09T09:34:46.000+09:00